Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC
Clinical trial NCT04142060 · TERMINATED
Trial details
- NCT number
- NCT04142060
- Sponsor
- SOLTI Breast Cancer Research Group
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-01
- Primary completion
- 2022-10-10
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.